JFHOD (Journées Francophones d’Hépato-gastroentérologie et d’Oncologie Digestive) 2019

Novartis announces presentation of new Lutathera® NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden

Novartis today announced presentation of a new analysis of Lutathera® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden.

57. Jahrestagung der Deutschen Gesellschaft für NuklearMedizin

5èmes Journées Françaises de Médecine Nucléaire

16th ENETS Annual Conference

European Neuroendocrine Tumor Society (ENETS)

2019 Gastrointestinal Cancers Symposium

Congrès National GTE (Groupe d’études des Tumeurs Neuroendocrines) 2018

Advanced Accelerator Applications Announces First Patients Dosed in Two Clinical Studies with PSMA-R2 for Prostate Cancer – Second Theragnostic Program for Oncology Enters the Clinic

AAA today announced that the first patients have been dosed in two Phase I/II clinical studies of radiolabeled PSMA-R2, a urea-based ligand of Prostate-Specific Membrane
Antigen (PSMA), which is commonly expressed on prostate cancer cells.

Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

Novartis today announced that the Journal of Clinical Oncology has published results of an analysis of the impact of Lutathera® (lutetium Lu 177 dotatate*) treatment on time to deterioration in HRQoL in the pivotal phase III NETTER-1 trial. The data demonstrate that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients with progressive midgut Neuroendocrine tumors (NETs) compared to octreotide LAR alone[1]. Lutathera is the first Peptide Receptor Radioisotope Therapy (PRRT) to receive regulatory registration, with approval by the European Commission in September 2017 and by the US Food and Drug Administration (FDA) in January 2018. Lutathera is an Advanced Accelerator Applications product.

2018 NANETS Annual Multidisciplinary NET Disease Symposium